Bessemer Group Inc. Has $2.68 Million Holdings in Integra LifeSciences Holdings Corporation (IART)

Bessemer Group Inc. reduced its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 4.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,100 shares of the life sciences company’s stock after selling 2,700 shares during the period. Bessemer Group Inc. owned 0.07% of Integra LifeSciences Holdings Corporation worth $2,680,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its stake in shares of Integra LifeSciences Holdings Corporation by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock worth $104,000 after purchasing an additional 1,400 shares during the last quarter. Riverhead Capital Management LLC boosted its stake in shares of Integra LifeSciences Holdings Corporation by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock worth $131,000 after purchasing an additional 799 shares during the last quarter. LS Investment Advisors LLC boosted its stake in shares of Integra LifeSciences Holdings Corporation by 4.6% during the 2nd quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock worth $138,000 after purchasing an additional 111 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Integra LifeSciences Holdings Corporation by 8.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after purchasing an additional 218 shares during the last quarter. Finally, Whittier Trust Co. acquired a new stake in shares of Integra LifeSciences Holdings Corporation during the 3rd quarter worth about $169,000. 83.60% of the stock is currently owned by institutional investors.

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $50.00 price target (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Thursday. UBS AG reaffirmed a “buy” rating and set a $57.00 price target on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, October 31st. Wells Fargo & Company cut shares of Integra LifeSciences Holdings Corporation from an “outperform” rating to a “market perform” rating in a research note on Sunday, October 29th. Jefferies Group LLC reaffirmed a “buy” rating and set a $56.00 price target on shares of Integra LifeSciences Holdings Corporation in a research note on Sunday, October 29th. Finally, TheStreet cut shares of Integra LifeSciences Holdings Corporation from a “b” rating to a “c+” rating in a research note on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $53.82.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded down $1.26 during mid-day trading on Monday, hitting $47.59. 407,400 shares of the stock traded hands, compared to its average volume of 612,900. The stock has a market cap of $3,734.74, a price-to-earnings ratio of 26.29, a P/E/G ratio of 2.07 and a beta of 0.64. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The business had revenue of $278.83 million during the quarter, compared to analysts’ expectations of $286.00 million. During the same quarter in the previous year, the business posted $0.93 EPS. The company’s quarterly revenue was up 11.4% on a year-over-year basis. equities analysts expect that Integra LifeSciences Holdings Corporation will post 1.87 earnings per share for the current year.

In other Integra LifeSciences Holdings Corporation news, Director Barbara B. Hill purchased 10,768 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The shares were purchased at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the acquisition, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 21.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Bessemer Group Inc. Has $2.68 Million Holdings in Integra LifeSciences Holdings Corporation (IART)” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/11/13/bessemer-group-inc-has-2-68-million-holdings-in-integra-lifesciences-holdings-corporation-iart.html.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply